The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation

J Neuroinflammation. 2018 Jul 12;15(1):206. doi: 10.1186/s12974-018-1246-x.

Abstract

Background: The steroid hormone estrogen (17-β-estradiol, E2) provides neuroprotection against cerebral ischemic injury by activating estrogen receptors. The novel estrogen receptor G protein-coupled receptor 30 (GPR30) is highly expressed in the brain and provides acute neuroprotection against stroke. However, the underlying mechanisms remain unclear.

Methods: In this study, ovariectomized female mice were subjected to middle cerebral artery occlusion (MCAO), and E2, G1, and ICI182780 were administered immediately upon reperfusion. The infarction volume, neurological scores, and neuronal injuries were examined. Primary microglial cells were subjected to oxygen-glucose deprivation (OGD), and the drugs were administered immediately upon reintroduction. The pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 in penumbra and microglia were assessed by ELISA. The cell viability and lactose dehydrogenase (LDH) release of neurons co-cultured with microglia were analyzed using cell counting kit-8 (CCK8) and LDH release assays. Microglial activation as well as GPR30, Iba1, and Toll-like receptor 4 (TLR4) protein expression and TLR4 mRNA expression were detected. Additionally, NF-κB activity was detected in lipopolysaccharide (LPS)-activated microglia after the activation of GPR30.

Results: GPR30 was highly expressed in microglia and significantly increased after ischemic injury. The activation of GPR30 significantly reduced the infarction volume, improved the neurological deficit, and alleviated neuronal injuries. Moreover, GPR30 activation significantly reduced the release of TNF-α, IL-1β, and IL-6 from ischemic penumbra and microglia subjected to OGD and alleviated neuronal injury as assessed using the CCK8 and LDH assays. Finally, the activation of GPR30 relieved microglial activation, reduced Iba1 and TLR4 protein expression and TLR4 mRNA levels, and inhibited NF-κB activity.

Conclusions: Microglial GPR30 exerts acute neuroprotective effects by inhibiting TLR4-mediated microglial inflammation, which indicates that GPR30 may be a potential target for the treatment of ischemic stroke.

Keywords: Estrogen; GPR30; Microglial inflammation; Stroke; TLR4.

MeSH terms

  • Animals
  • Animals, Newborn
  • Cell Hypoxia / drug effects
  • Cells, Cultured
  • Coculture Techniques
  • Disease Models, Animal
  • Estradiol / pharmacology
  • Estrogen Receptor Antagonists / pharmacology
  • Female
  • Fulvestrant / pharmacology
  • Glucose / deficiency
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / metabolism*
  • Inflammation / etiology
  • Inflammation / pathology*
  • Lipopolysaccharides / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • Microglia / drug effects
  • Microglia / pathology*
  • Neurons / drug effects
  • Ovariectomy
  • Receptors, Estrogen / metabolism*
  • Receptors, G-Protein-Coupled / metabolism*
  • Toll-Like Receptor 4 / metabolism*

Substances

  • Estrogen Receptor Antagonists
  • GPER1 protein, mouse
  • Lipopolysaccharides
  • Receptors, Estrogen
  • Receptors, G-Protein-Coupled
  • Tlr4 protein, mouse
  • Toll-Like Receptor 4
  • Fulvestrant
  • Estradiol
  • Glucose